keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GLP-1(28-36)amide, a C-terminal nonapeptide derived from the cleavage of GLP-1 by neutral endopeptidase (NEP), is a significant product. It functions as an antioxidant and primarily targets the mitochondrion, where it effectively inhibits mitochondrial permeability transition (MPT). This compound exhibits anti-diabetic properties and demonstrates cardioprotection effects[1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | $ 237.00 | |
10 mg | Inquiry | $ 397.00 |
Description | GLP-1(28-36)amide, a C-terminal nonapeptide derived from the cleavage of GLP-1 by neutral endopeptidase (NEP), is a significant product. It functions as an antioxidant and primarily targets the mitochondrion, where it effectively inhibits mitochondrial permeability transition (MPT). This compound exhibits anti-diabetic properties and demonstrates cardioprotection effects[1]. |
In vitro | Unlike DPP-IV, the enzyme NEP cleaves GLP-1(7-36)amide or GLP-1(9-36)amide into GLP-1(28-36)amide and is prevalent in endothelial, vascular smooth muscle, cardiac, and renal epithelial cells[1]. Treatment with GLP-1(28-36)amide (100 nM) on hepatocytes for 24 hours specifically influences mitochondrial oxidative metabolism, including gluconeogenesis within hepatocyte mitochondria[1]. Moreover, the plasma half-life of GLP-1(28-36)amide in human hepatocytes (t1/2 = 24 min) surpasses its duration in mouse hepatocytes (t1/2 = 13 min)[1]. |
In vivo | Administering GLP-1(28-36)amide at 18.5 nmol/kg body weight/day for 9 weeks significantly reduces hepatic steatosis in diet-induced obese mice. Similarly, daily intraperitoneal injections of 18 nmol/kg GLP-1(28-36)amide over 9 weeks enhance pancreatic β cell mass and proliferation, showcasing a cytoprotective effect in a β-cell injury diabetic mouse model. An in vivo study further reveals that a six-week course of GLP-1(28-36)amide at 18.5 nmol/kg in high-fat diet-fed mice significantly improves hepatic glucose metabolism, an effect linked with increased cAMP levels and PKA target phosphorylation. Moreover, a brief 20-minute administration of GLP-1(28-36)amide to male C57BL6/J mice followed by a procedure involving 30 minutes of global ischemia and 40 minutes of reperfusion results in a significantly enhanced recovery of left ventricular developed pressure (LVDP) in GLP-1(28-36)amide treated hearts compared to controls[1]. |
Molecular Weight | 1088.37 |
Formula | C54H85N15O9 |
CAS No. | 1225021-13-5 |
keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GLP-1(28-36)amide 1225021-13-5 GLP-1amide GLP1(2836)amide GLP 1(28 36)amide inhibitor inhibit